Which has higher valuation and earnings, NTRA or GILD?

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.75 -$208.16M -$1.36 N/A Gilead Sciences $30.46B 5.95 $8.51B -$2.67 N/A

Is NTRA or GILD more profitable?

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Gilead Sciences -10.64% -2.11% -0.75%

Does the media favor NTRA or GILD?

In the previous week, Gilead Sciences had 74 more articles in the media than Natera. MarketBeat recorded 105 mentions for Gilead Sciences and 31 mentions for Natera. Gilead Sciences' average media sentiment score of 1.35 beat Natera's score of 1.34 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 82 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRTX or NTRA?

In the previous week, Vertex Pharmaceuticals had 31 more articles in the media than Natera. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 31 mentions for Natera. Vertex Pharmaceuticals' average media sentiment score of 1.52 beat Natera's score of 1.34 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 56 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor NTRA or REGN?

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Natera. MarketBeat recorded 75 mentions for Regeneron Pharmaceuticals and 31 mentions for Natera. Natera's average media sentiment score of 1.34 beat Regeneron Pharmaceuticals' score of 0.89 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 47 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better valuation & earnings, NTRA or ARGX?

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.75 -$208.16M -$1.36 N/A argenex $4.25B 15.31 $1.29B $26.04 39.93

Is NTRA or ARGX more profitable?

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% argenex 32.19% 43.59% 36.66%

Does the media prefer NTRA or ARGX?

In the previous week, argenex had 11 more articles in the media than Natera. MarketBeat recorded 42 mentions for argenex and 31 mentions for Natera. Natera's average media sentiment score of 1.34 beat argenex's score of 0.81 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive argenex 13 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or NTRA?

In the previous week, Natera had 19 more articles in the media than Revolution Medicines. MarketBeat recorded 31 mentions for Natera and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Natera's score of 1.34 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Natera (NTRA) Competitors

$332.03 +7.19 (+2.21%)

As of 08/21/2026 04:00 PM Eastern

Compare

NTRA vs. GILD, VRTX, REGN, ARGX, and RVMD

Should you buy Natera stock or one of its competitors? Natera's main competitors and comparable companies include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Natera compare to Gilead Sciences?

Natera (NASDAQ:NTRA) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Natera currently has a consensus price target of $319.38, indicating a potential downside of 3.81%. Gilead Sciences has a consensus price target of $158.04, indicating a potential upside of 8.16%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Gilead Sciences	-10.64%	-2.11%	-0.75%

In the previous week, Gilead Sciences had 74 more articles in the media than Natera. MarketBeat recorded 105 mentions for Gilead Sciences and 31 mentions for Natera. Gilead Sciences' average media sentiment score of 1.35 beat Natera's score of 1.34 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	82 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A
Gilead Sciences	$30.46B	5.95	$8.51B	-$2.67	N/A

99.9% of Natera shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Natera on 10 of the 17 factors compared between the two stocks.

How does Natera compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Vertex Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.59	$3.95B	$17.18	31.90
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

Vertex Pharmaceuticals currently has a consensus target price of $563.50, suggesting a potential upside of 2.82%. Natera has a consensus target price of $319.38, suggesting a potential downside of 3.81%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vertex Pharmaceuticals has a net margin of 35.00% compared to Natera's net margin of -7.11%. Vertex Pharmaceuticals' return on equity of 23.09% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Vertex Pharmaceuticals had 31 more articles in the media than Natera. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 31 mentions for Natera. Vertex Pharmaceuticals' average media sentiment score of 1.52 beat Natera's score of 1.34 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	56 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Natera on 12 of the 17 factors compared between the two stocks.

How does Natera compare to Regeneron Pharmaceuticals?

Natera (NASDAQ:NTRA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Regeneron Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A
Regeneron Pharmaceuticals	$14.34B	5.99	$4.50B	$40.46	20.61

99.9% of Natera shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Natera's net margin of -7.11%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Natera. MarketBeat recorded 75 mentions for Regeneron Pharmaceuticals and 31 mentions for Natera. Natera's average media sentiment score of 1.34 beat Regeneron Pharmaceuticals' score of 0.89 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	47 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Natera currently has a consensus price target of $319.38, indicating a potential downside of 3.81%. Regeneron Pharmaceuticals has a consensus price target of $801.70, indicating a potential downside of 3.88%. Given Natera's stronger consensus rating and higher probable upside, analysts plainly believe Natera is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Regeneron Pharmaceuticals beats Natera on 10 of the 17 factors compared between the two stocks.

How does Natera compare to argenex?

Natera (NASDAQ:NTRA) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, argenex had 11 more articles in the media than Natera. MarketBeat recorded 42 mentions for argenex and 31 mentions for Natera. Natera's average media sentiment score of 1.34 beat argenex's score of 0.81 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
argenex	13 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera currently has a consensus price target of $319.38, suggesting a potential downside of 3.81%. argenex has a consensus price target of $1,118.28, suggesting a potential upside of 7.55%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A
argenex	$4.25B	15.31	$1.29B	$26.04	39.93

Natera has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

99.9% of Natera shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
argenex	32.19%	43.59%	36.66%

Summary

argenex beats Natera on 11 of the 16 factors compared between the two stocks.

How does Natera compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Revolution Medicines presently has a consensus target price of $167.89, indicating a potential downside of 19.85%. Natera has a consensus target price of $319.38, indicating a potential downside of 3.81%. Given Natera's higher probable upside, analysts plainly believe Natera is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

In the previous week, Natera had 19 more articles in the media than Revolution Medicines. MarketBeat recorded 31 mentions for Natera and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Natera's score of 1.34 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.38% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Natera	-7.11%	-11.38%	-7.87%

Natera has higher revenue and earnings than Revolution Medicines. Natera is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Natera beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Natera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRA vs. The Competition

Export

Metric	Natera	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.86B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	-244.14	11.62	272.88	24.24
Price / Sales	20.75	1,338.17	618.96	99.76
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	26.27	16.80	13.05	6.20
Net Income	-$208.16M	-$12.50M	$3.47B	$348.59M
7 Day Performance	7.13%	3.29%	2.09%	0.08%
1 Month Performance	25.44%	8.23%	6.64%	3.88%
1 Year Performance	100.50%	55.05%	25.02%	16.98%

Natera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRA Natera	2.5992 of 5 stars	$332.03 +2.2%	$319.38 -3.8%	+100.5%	$47.86B	$2.31B	N/A	6,140	News Coverage Positive News
GILD Gilead Sciences	4.1356 of 5 stars	$138.92 +0.4%	$158.04 +13.8%	+27.3%	$171.56B	$29.44B	N/A	17,000	News Coverage Positive News Insider Trade Analyst Revision
VRTX Vertex Pharmaceuticals	4.2032 of 5 stars	$515.55 +1.9%	$563.50 +9.3%	+38.7%	$128.36B	$12.00B	30.01	6,400	News Coverage Positive News
REGN Regeneron Pharmaceuticals	4.0806 of 5 stars	$805.93 +0.3%	$801.70 -0.5%	+41.5%	$82.72B	$14.34B	19.92	15,410	Trending News Ex-Dividend
ARGX argenex	4.2634 of 5 stars	$987.84 +16.0%	$1,072.72 +8.6%	+57.5%	$53.26B	$4.25B	37.94	1,863	Trending News Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and RVMD

How does Natera compare to Gilead Sciences?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Summary

How does Natera compare to argenex?

Summary

How does Natera compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and RVMD

How does Natera compare to Gilead Sciences?

Do analysts rate NTRA or GILD?

Is NTRA or GILD more profitable?

Does the media favor NTRA or GILD?

Which has more volatility and risk, NTRA or GILD?

Which has higher valuation and earnings, NTRA or GILD?

Do institutionals & insiders believe in NTRA or GILD?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Do insiders and institutionals hold more shares of VRTX or NTRA?

Which has more volatility & risk, VRTX or NTRA?

Which has preferable earnings and valuation, VRTX or NTRA?

Do analysts recommend VRTX or NTRA?

Is VRTX or NTRA more profitable?

Does the media refer more to VRTX or NTRA?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Which has better earnings and valuation, NTRA or REGN?

Do institutionals & insiders believe in NTRA or REGN?

Which has more volatility & risk, NTRA or REGN?

Is NTRA or REGN more profitable?

Does the media favor NTRA or REGN?

Do analysts prefer NTRA or REGN?

Summary

How does Natera compare to argenex?

Does the media prefer NTRA or ARGX?

Do analysts prefer NTRA or ARGX?

Which has better valuation & earnings, NTRA or ARGX?

Which has more volatility and risk, NTRA or ARGX?

Do insiders and institutionals have more ownership in NTRA or ARGX?

Is NTRA or ARGX more profitable?

Summary

How does Natera compare to Revolution Medicines?

Do analysts prefer RVMD or NTRA?

Which has more volatility & risk, RVMD or NTRA?

Does the media refer more to RVMD or NTRA?

Is RVMD or NTRA more profitable?

Which has stronger valuation & earnings, RVMD or NTRA?

Do insiders & institutionals have more ownership in RVMD or NTRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools